Over the last months, I’ve written five articles on Seeking Alpha as part of my personal challenge. This means I’m at 10% of my journey, but i’ll have to step up my game.
As a short term goal I will write 8 articles in April. For now, please find the first 5 published on Seeking Alpha below.
Beiersdorf Remains Fairly Valued Despite Sales Growth Acceleration
- Beiersdorf has a strong portfolio of brands working for it in 170 countries.
- The company is beating its peers in terms of revenue growth, but only very recently (+5.2% for the first three quarters YoY).
- This debt free and family-controlled business could easily raise dividends to match the historical pay-out ratio.
- Despite better sales, I believe the company to be fairly valued and would only buy on a dip towards €85.
ABB Ltd Is Preparing Itself For A Profitable Decade
- ABB Ltd is a buy in the $24 to $26 range.
- Over the last 10 years, the dividend has grown 12.12% annually.
- The company has positioned itself nicely in niches which will grow over the next decade.
- The company aims to become #1 and 2# in its niches.
- Recent M&A activity makes the stock difficult to value.
Is There A Reason For This Hidden Champion To Lag The Market? I Don’t Believe So
- Corticeira Amorim continues to grow revenues and profits.
- The company is lagging the market for no apparent reason.
- A strong moat and low debt mean the risk/reward is attractive.
- The company is yielding 2.62% and will very likely hike its dividend again this year (7-year average: 14.6% annually dividend growth).
- I think it’s likely the company will return to its 52-week high in the coming 12 months, presenting nearly 30% upside.
Link to article Corticeira Amorim.
Tableau Software Struggles With Profitability As Revenue Growth Slows Down
- Total annual recurring revenue is up 45% year over year at $596.2 million.
- Investments in R&D rose 10% year over year.
- The market leader in Business Intelligence software is transitioning into a SaaS model instead of a licensing and service model.
- All of the above don’t make it a screaming buy in this environment.
Link to article Tableau Software.
Reckitt Benckiser Has Value If You Can Live With The Debt (But You Shouldn’t)
- RB’s sales growth is weakening and was flat like-for-like over 2017.
- Debt remains elevated at £11 billion (or $15.4 billion) and around 3.5 times EBITDA.
- The company is hoping to grow the business primarily in Asia following the Mead Johnson (MJN) integration.
- RB pulls out of Pfizer Consumer Healthcare take-over discussions.
Link to article RB.